Healthcare Tech Focus Santé shows a sustained focus on early-stage healthcare technology, biopharma, and digitally enabled services, with recent investments in Endovascular Engineering, Graici, beHuman, and Sonire Therapeutics. This portfolio tilt creates opportunities for sales teams to engage portfolio companies on go-to-market, regulatory readiness, data strategy, and clinical development support.

US Expansion Focus Santé actively supports US market entry for portfolio companies, exemplified by Sonire's planned US footprint and its Japan-based clinical foundation. This signals demand for regulatory, reimbursement, and market-access services, offering BD opportunities to connect portfolio firms with CROs, payers, and strategic partners to accelerate US scaling.

Capital and Co-invest With roughly $1B in AUM across five funds and a Fund V close, Santé has strong capital capacity and a track record of follow-on support. This presents opportunities for co-investment, strategic partnerships, and cross-portfolio financing to help portfolio companies reach critical growth milestones.

AI and Data Momentum Investments like Graici highlight Santé’s interest in AI-driven data platforms and data interoperability in public benefits, alongside beHuman’s preventive-care focus. This indicates appetite for data engineering, privacy, security, and regulatory-compliant analytics solutions to strengthen portfolio performance.

Investor Network Endovascular Engineering’s Series C involved multiple co-leads and strategic investors, including Santé, underscoring Santé’s ability to mobilize a diverse investor ecosystem. BD opportunities include facilitating strategic partnerships, licensing, or distribution deals that leverage Santé’s network to accelerate portfolio growth.